ArticleBMC women's health2026
The relationship between different hormone receptors in breast cancer patients and ovarian response before chemotherapy; a retrospective cohort study.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study intended to investigate the relationship between the hormone receptors (including estrogen and progesterone receptors (ER/PR), and human epidermal growth factor receptor-2 (HER2) or triple-negative breast cancer (TNBC)) status of BC patients and their response to ovarian stimulation before chemotherapy.
methodsThis is a retrospective cohort study. All patients with pathologically confirmed BC who underwent fertility preservation elected for oocyte or embryo cryopreservation were included in the study. All patients were stratified according to the immunohistochemically expression of receptors. We divided the patients into the exposure groups of ER+ (n = 89)/ ER- (n = 39), PR+ (n = 85)/ PR- (n = 43), HER2+ (n = 46)/ HER2- (n = 82), TNBC (n = 27)/ non-TNBC (n = 101), and Ki67 < 20% (n = 36)/ Ki67 ≥ 20% (n = 74). The primary outcome was total oocytes retrieved.
resultsIn total, 128 patients with BC were enrolled in this study. Based on the patients' baseline characteristics, as well as the ovarian stimulation cycle parameters and their outcomes, no significant differences were observed among patients according to hormone receptor status. The HER2 + group exhibited a significantly higher number of dominant follicles on the trigger day than the HER2- group (p = 0.035); however, no significant differences were noted regarding oocyte count and maturity.
conclusionsThe findings of the current study show that the determinants of BC prognosis, such as ER, PR, TNBC, and Ki67 status, have no effect on patients' responses to ovarian stimulation. Nevertheless, despite achieving an acceptable number of dominant follicles on the day of trigger, HER2 + status can affect the number of retrieved oocytes, particularly the number of mature oocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.